

AMENDMENTS TO THE CLAIMS

1 (Currently Amended). A compound 8 to 50 nucleobases in length targeted to a coding region of a nucleic acid molecule encoding human acyl CoA cholesterol acyltransferase-2 (SEQ ID NO: 3), wherein said compound specifically hybridizes with said region and inhibits the expression of human acyl CoA cholesterol acyltransferase-2 by at least 40%.

2 (Original). The compound of claim 1 which is an antisense oligonucleotide.

3 (Canceled).

C1
4 (Original). The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

5 (Original). The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

6 (Original). The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

7 (Original). The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

8 (Original). The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

DOCKET NO: ISPH-0588

PATENT

9(Original). The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

10(Original). The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

11(Canceled).

12(Original). A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

13(Original). The composition of claim 12 further comprising a colloidal dispersion system.

14(Original). The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Claims 15-20(Canceled).